Breast Cancer

BREAST CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Overcoming Obstacles to Health Equity in Breast Cancer Prevention and Control

The current scientific evidence may not be generalizable to underrepresented groups.
On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management

Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials

A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP

Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates

GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.

VIDEO SERIES

The Phase 3 PlanB Trial

Continue to Work?

2016 SABCS: Clinical Insights Telli

2016 SABCS: Clinical Insights Oregan

HER2-positive Metastatic and TNBC

Frontline Treatments

Treatment-related Neuropathy

ER-positive, HER2-negative

Emerging Medicines

Triple-negative Breast Cancer

Insights from the Lab and Clinic

Trastuzumab Resistance

Biologic Role of HER2

Strategies in Management

BREAST CANCER NEWS

The ASCO/CAP Expert Panel continues to recommend IHC as the only primary screening test for predicting benefit of endocrine therapy in breast cancer.

Radiotherapy Plus Trastuzumab Did Not Significantly Reduce Ipsilateral Breast Tumor Recurrence Rate in HER2+ DCIS

July 30, 2021

As post-transplant medications are used to reduce the body’s immune reaction to a foreign organ, the

Surgery May Improve Survival in Older Patients With Invasive Breast Cancer

July 29, 2021

The researchers found 21 early-onset cancer cases carrying the novel pathogenic TP53 variant.

Addition of Pembrolizumab ‘Should Be New Standard of Care’ for Early Triple-Negative Breast Cancer

July 28, 2021

Keytruda Combo Approved for High-Risk Early-Stage Triple-Negative Breast Cancer

July 28, 2021

Immunotherapy Increasingly Used in Cancer Care

Extended Bisphosphonate Treatment Does Not Improve Survival in High-Risk Early Breast Cancer

July 23, 2021

Next post in Breast Cancer

As post-transplant medications are used to reduce the body’s immune reaction to a foreign organ, the

Surgery May Improve Survival in Older Patients With Invasive Breast Cancer